Core Insights - The company reported a decline in revenue and net profit for the first three quarters of 2025, with total revenue at RMB 19.89 billion, down 12.3% year-on-year, and net profit attributable to shareholders at RMB 3.511 billion, down 7.1% [1] Financial Performance - Total revenue for the first three quarters was RMB 19.89 billion, a decrease of 12.3% compared to the previous year [1] - Net profit attributable to shareholders was RMB 3.511 billion, reflecting a year-on-year decline of 7.1% [1] - Adjusted net profit was RMB 3.079 billion, down 23% year-on-year [1] - Basic earnings per share were RMB 0.3072, a decrease of 4.1% from the same period last year [1] Business Segments - Revenue from the pharmaceutical business was RMB 15.45 billion, down 17.2%, primarily due to centralized procurement and price adjustments in the national medical insurance drug list [1] - Revenue from raw material products was RMB 3.006 billion, an increase of 10.3%, with vitamin C sales reaching RMB 1.788 billion, up 22.3% [1] - Revenue from functional foods and other businesses was RMB 1.435 billion, reflecting an 11.2% increase [1] Research and Development - R&D expenses increased by 7.9% to RMB 4.185 billion, accounting for 27.1% of pharmaceutical business revenue [2] - The company has nearly 90 products in various stages of clinical trials, with 14 submitted for market approval and over 30 key products in the registration clinical phase [2]
石药集团前三季度营收净利双双下降，成药业务收入降幅明显